Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.38 |
| ▸ | USP7 | Q93009 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 6/20 | 0.36 |
| ▸ | CTSL | P07711 | 5/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173740 | 0.89 | CTSK (0.47) | CTSKCTSSCTSLCTSBHDAC8 | |
| SCHEMBL3920108 | 0.88 | USP7 (0.42) | CTSKUSP7CTSSCTSLCTSB | |
| Trifluoroacetic Acid SCHEMBL3176999 | 0.86 | CTSK (0.42) | CTSKCTSSCTSLCTSBHDAC8 | |
| SCHEMBL8211313 | 0.86 | FNTA (0.39) | CTSKUSP7CTSSCTSLCTSB | |
| SCHEMBL3169583 | 0.84 | CTSS (0.41) | CTSKCTSSCTSLCTSBGCGR | |
| SCHEMBL3176722 | 0.83 | CTSK (0.43) | CTSKCTSSCTSLCTSBHDAC6 | |
| SCHEMBL3172936 | 0.83 | CTSS (0.39) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3159544 | 0.82 | CTSK (0.41) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3169251 | 0.82 | CTSK (0.42) | CTSKCTSSCTSLCTSBF10 | |
| SCHEMBL3173212 | 0.82 | CTSS (0.39) | CTSKCTSSCTSLCTSBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | claimed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | SERPINB1, CTRL, PRSS1 | CTSK 65/4885USP7 320/4885CTSS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.